Enterome fortifies Takeda relationship with $50M upfront to co-develop Crohn's drug
Privately held French biotech Enterome SA has scored a cool $50 million upfront to co-develop its experimental early-stage Crohn’s disease drug with Takeda in its second collaboration with the Japanese drugmaker.
The microbiome-focused Enterome — which already boasts of collaborations with big Pharma players such as Johnson & Johnson $JNJ, Bristol-Myers $BMY — is set to work with Takeda $TKPYY in developing EB8018, a small molecule designed to selectively disarm virulent bacteria in the gut that can cause inflammation, without disrupting the local microbiome.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
